Background

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive and common type of B-cell lymphoma.
• Patients with relapsed/refractory DLBCL who are ineligible for stem cell transplantation have an especially poor prognosis of usually a few months.
• iR ²  is a combination of 3 European Medicines Agency-approved and FDA-approved drugs—ibrutinib+lenalidamide+rituximab—being tested together...